Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Etuvetidigene Autotemcel→

Etuvetidigene Autotemcel Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
Not available
Molecular formula
Not available
Molecular weight
Not available
Drug class
Autologous CD34+ haematopoietic stem-cell gene therapylentiviral WAS gene addition product
Mechanism of action
Autologous CD34+ cells are transduced ex vivo with a lentiviral vector carrying functional WAS complementary DNA. Reinfused gene-modified stem cells engraft and generate haematopoietic progeny expressing WAS protein, addressing the underlying Wiskott-Aldrich syndrome gene defect.
Indications / reported uses
  • Treatment of paediatric patients aged 6 months and older and adults with Wiskott-Aldrich syndrome caused by a WAS gene mutation, for whom HSCT is appropriate and no suitable HLA-matched related donor is available

Sources: US FDA — WASKYRA product information · US FDA Purple Book — WASKYRA · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Etuvetidigene Autotemcel Environmental Risk Assessment (ERA) (the Etuvetidigene Autotemcel ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.